FUNGAL OTITIS EXTERNA MARKET ANALYSIS

Fungal Otitis Externa Market, by Drug Type (Ear Drops (Clotrimazole, Fluconazole, and Acetic Acid (2%)), Oral Medications (Itraconazole and NSAIDS), Topical Medications, and Late Stage Pipeline Drugs), by Fungus Type (Aspergillus and Candida), by Route of Administration (Otic, Oral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Jul 2021
Code : CMI4548
Pages :166
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Fungal Otitis Externa Market- Restraint

Complications associated with drugs used in the treatment of fungal otitis externa and increasing generic competition is expected to hinder growth of the global fungal otitis externa market. Presence of generic drugs, at much lower price compared to branded drugs, in the market for the treatment of fungal otitis externa is a major factor, which is expected to hamper the market growth in the near future For instance, on July 2012, Mylan Inc., its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Itraconazole Capsules, 100 mg. This product is the generic version of Janssen Pharmaceutical Inc.'s Sporanox and is indicated for the treatment of fungal infections.